This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s […]
Biotechnology in Countries Beginning with “I” – Part 9: Iran Read Post »
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Once in a Blue Moon: When BIO and DIA Worlds Collide #BIO2015 #DIA2015 Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Dyslipidaemia: Focus shifts from LDL-C to HDL-C
Go to paperABSTRACT: In this current analysis of the antidyslipidaemics market, a shift in focus from lo…
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
Pseudo-controversy continues to rage over whether foods from plants and animals genetically engineered with the newest molecular techniques should have to be labeled as such. The battles, fought in the media, state legislatures, referendum issues, and in federal courts, have been largely fomented and funded by the organic agriculture and food industries. All but one of the proposals to require labeling in the United States have failed, and that exception is being challenged in a federal court . In spite of these failures and the fact that mandatory labeling fails every test –scientific, economic, legal and common-sense–the true believers soldier on.
A ‘Genetically Engineered’ Label: Way More Expensive Than You Think Read Post »
The regenerative medicine space is one that is set to explode with considerable innovation and profitability for shrewd biotechnologists. I had the opportunity to speak with Michael West, PhD., CEO of BioTime (BTX) and found a man passionate about rege…
BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision Read Post »